Low grade glioma
Therapeutic area
Neurology
Rare disease
No
- Definition
- A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Low grade glioma
- Therapeutic area
- Neurology
- low grade glioma
- benign glioma
- glioma, benign
- High and Low Grade Glioma
- Low Grade Glioma (LGG)
- low-grade glioma
- Metastatic Low Grade Glioma
- Progressive Low-Grade Glioma
- Recurrent Low Grade Glioma
- Recurrent Low-Grade Glioma
- Refractory Low Grade Glioma
- Severity
- Severe
- Neurology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0021637
- Parent condition
- MONDO:0021042
Related records
Broader conditions (11)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Glioma
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Nervous system disorder
- Nervous system neoplasm
- Neuroepithelial neoplasm
Narrower conditions (65)
- 22q-related schwannomatosis
- Acoustic neuroma
- Adult oligodendroglioma
- Adult spinal cord ependymoma
- Anaplastic oligoastrocytoma
- Angiocentric glioma
- Benign mediastinal psammomatous neurilemmoma
- Brain oligodendroglioma
- Brain stem ependymoma
- Cellular ependymoma
- Cellular schwannoma
- Cerebellar pilocytic astrocytoma
- Childhood ependymoma
- Childhood low-grade glioma
- Childhood oligodendroglioma
- Childhood pilocytic astrocytoma
- Chordoid glioma of the third ventricle
- Clear cell ependymoma
- Corpus callosum oligodendroglioma
- Diffuse astrocytoma
Trials (34)
- (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
- A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
- A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
- A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas
- A Vaccine Trial for Low Grade Gliomas
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
- Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma
- Everolimus With and Without Temozolomide in Adult Low Grade Glioma
- Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma
- Fluorescence Spectroscopy Guided Surgery
- Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
- General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
- Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
- MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- Mind-Body Intervention in Glioma Couples
- Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
- Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
- Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
Approved drugs (4)
- Dabrafenib mesylate
- Temozolomide
- Tovorafenib
- Trametinib dimethyl sulfoxide
Drugs in development (48)
- Bevacizumab Phase 2
- Binimetinib Phase 1
- Capecitabine Phase 1
- Carboplatin Phase 3
- Carmustine Phase 2
- Cobimetinib Phase 1
- Cyclophosphamide Phase 1
- Dabrafenib Phase 1
- Dexamethasone Phase 2
- Endostatin Phase 2
- Erlotinib Phase 1
- Erlotinib hydrochloride Phase 1
- Everolimus Phase 2
- Fluciclovine F18 Early phase 1
- Hiltonol Phase 2
- Hydroxychloroquine Phase 1
- Hydroxyurea Phase 2
- IDH305 Phase 2
- Imatinib mesylate Phase 2
- Infigratinib Phase 1